Fingerprint
Dive into the research topics of 'Phase III study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer - PROSELICA'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically